The National Agency for Food and Drug Administration and Control (NAFDAC) has urged Nigerians to stop circulating misinformation about Camosunate, a malaria medication, being banned from the country.
In a clarification document signed by Prof. Mojisola Adeyeye, Director General and Chief Executive Officer of NAFDAC on Saturday, it was stated that Camosunate or formulations containing artesunate-amodiaquine combination have not been banned.
This notification was made following reports circulating on social media platforms that the malaria medication has been banned in Nigeria, causing confusion and concern amongst members of the public.
However, the agency noted in its clarification that some of the symptoms mentioned in the viral content may be common side-effects of Camosunate.
Read Also: Transfer: Borriello Urges Juventus to Consider Osimhen
The side effects include, Nausea Vomiting Diarrhoea Abdominal pain Headache Dizziness Sleepiness Loss of appetite.
Meanwhile, if any adverse drug reaction is suspected, NAFDAC has urged people to report these to them so that proper assessments can take place.
Members of the public and Health care professionals are encouraged to report suspected reactions using the NAFDAC Med Safety App downloadable on android and iOS devices. Or visit your nearest NAFDAC office.
The agency has also urged members of the public to stop circulating this false information.
Those who shared the post should help in correcting this false information by sharing this clarification on the same platforms.
NAFDAC therefore urges responsible dissemination of information. It equally encourages members of the public to report suspected adverse drug reaction to make medicines safer in the country.
